Coloplast revenue grows 3.00 percent: Coloplast stock stood at DKK 472.20 on October 16, 2026

Published on 10/17/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBIT reached DKK 1.93 billion in nine months. Coloplast stock stood at DKK 472.20 on October 16, 2026, up 0.79 percent on Nasdaq Copenhagen.

Nine-month operating picture

Coloplast reported 3.00 percent revenue growth for the first nine months of fiscal 2025/26 on September 30, 2026.
EBIT before special items reached DKK 1.93 billion in the first nine months of fiscal 2025/26.
Coloplast stock stood at DKK 472.20 on October 16, 2026, up 0.79 percent versus the Nasdaq Copenhagen prior close.
Coloplast traded at a P/E ratio of 38.52 on October 16, 2026.

Reinraum-Produktion medizinischer Versorgungsprodukte in heller Fertigungshalle — Coloplast A/S (DK0060448595) zeigt hier moderne sterile Produktion medizinischer Versorgungsprodukte in heller Fertigungshalle, Illustration mit AI erstellt.

Coloplast (ISIN DK0060448595) reported revenue growth of 3.00 percent in the first nine months of fiscal 2025/26, reaching DKK 21.48 billion from DKK 20.91 billion a year earlier. The figures come from Coloplast and were presented on September 30, 2026. The stock last stood at DKK 472.20 on Nasdaq Copenhagen on October 16, 2026 at 4:59 p.m. CEST, up 0.79 percent from the prior close of DKK 468.50.

Operating growth meets margin pressure

Organic revenue growth was 6.00 percent in the first nine months, while reported growth was held back by a 3.00 percentage-point currency effect. EBIT before special items reached DKK 1.93 billion, up 1.00 percent from the prior-year period, according to Coloplast.

The reported EBIT margin before special items was 26.00 percent, compared with 28.00 percent a year earlier. Coloplast attributed pressure to currency effects and Kerecis-related factors, while adjusted free cash flow reached DKK 4.23 billion and represented 20.00 percent of revenue in the first nine months.

Stock sits 25.23 percent below high

The home-market quote places Coloplast 25.23 percent below its DKK 631.40 52-week high and 27.72 percent above its DKK 369.70 52-week low as of October 16, 2026. Trading volume was 262,479 shares, versus an average volume of 332,744 shares.

The valuation picture is mixed across the medical-technology comparison. Coloplast carried a P/E ratio of 38.52 and a market capitalization of DKK 106.4 billion on October 16, 2026. Essity traded at a P/E ratio of 15.65 with a market capitalization of SEK 186.9 billion, while ConvaTec carried a P/E ratio of 50.83 and a market capitalization of GBP 4.6 billion.

Comparison with peers

Coloplast: plus 0.79 percent, P/E 38.52, market capitalization DKK 106.4 billion

Essity (Nasdaq Stockholm, SEK): plus 0.58 percent, P/E 15.65, market capitalization SEK 186.9 billion

ConvaTec (London Stock Exchange, GBp): plus 0.51 percent, P/E 50.83, market capitalization GBP 4.6 billion

Next report date is November 3

The next annual report is scheduled for November 3, 2026, according to Affarsvarlden. Coloplast's fiscal 2025/26 guidance calls for organic revenue growth of 5.00 to 6.00 percent and EBIT growth of about 5.00 percent in constant currencies, before special items.

Price remains below yearly high

Coloplast's latest completed Nasdaq Copenhagen session combined a DKK 3.70 gain with a valuation that remains below the yearly high. The next report will test whether the company's 6.00 percent organic growth pace can support its full-year guidance.